收费全文 | 2740篇 |
免费 | 168篇 |
国内免费 | 24篇 |
耳鼻咽喉 | 37篇 |
儿科学 | 65篇 |
妇产科学 | 113篇 |
基础医学 | 313篇 |
口腔科学 | 64篇 |
临床医学 | 187篇 |
内科学 | 580篇 |
皮肤病学 | 45篇 |
神经病学 | 103篇 |
特种医学 | 150篇 |
外国民族医学 | 1篇 |
外科学 | 605篇 |
综合类 | 56篇 |
预防医学 | 201篇 |
眼科学 | 54篇 |
药学 | 206篇 |
中国医学 | 6篇 |
肿瘤学 | 146篇 |
2023年 | 23篇 |
2022年 | 58篇 |
2021年 | 94篇 |
2020年 | 70篇 |
2019年 | 100篇 |
2018年 | 158篇 |
2017年 | 95篇 |
2016年 | 78篇 |
2015年 | 90篇 |
2014年 | 126篇 |
2013年 | 140篇 |
2012年 | 189篇 |
2011年 | 189篇 |
2010年 | 112篇 |
2009年 | 99篇 |
2008年 | 145篇 |
2007年 | 143篇 |
2006年 | 136篇 |
2005年 | 128篇 |
2004年 | 116篇 |
2003年 | 101篇 |
2002年 | 77篇 |
2001年 | 21篇 |
2000年 | 22篇 |
1999年 | 22篇 |
1998年 | 14篇 |
1997年 | 8篇 |
1996年 | 18篇 |
1995年 | 21篇 |
1994年 | 11篇 |
1993年 | 16篇 |
1992年 | 29篇 |
1991年 | 14篇 |
1990年 | 24篇 |
1989年 | 26篇 |
1988年 | 22篇 |
1987年 | 20篇 |
1986年 | 21篇 |
1985年 | 15篇 |
1983年 | 11篇 |
1981年 | 9篇 |
1979年 | 13篇 |
1978年 | 12篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1974年 | 9篇 |
1970年 | 7篇 |
1968年 | 8篇 |
1967年 | 6篇 |
1966年 | 7篇 |
Background and study aims
Hepatitis C virus (HCV) infection is a severe problem among patients on maintenance haemodialysis who are at particular risk for blood-borne infections because of prolonged vascular access and potential for exposure to contaminated equipment. Occult hepatitis C virus infection (OCI) is defined as the presence of HCV RNA in liver or peripheral blood mononuclear cells (PBMCs) in the absence of detectable HCV antibody or HCV RNA in the serum. In this study, we aimed to investigate the existence of occult hepatitis C virus infection in PBMCs of haemodialysis (HD) patients in one center. Moreover, we tried to link the condition to risk factors associated with HCV infection in those patients.Patients and methods
We included 40 patients with renal diseases undergoing regular haemodialysis who were repeatedly anti-HCV negative. HCV RNA detection was tested by Quantitative Real time PCR in serum and PBMCs.Results
The results of this study revealed that 23% of our haemodialysis patients have occult hepatitis C virus infection. There was a highly significant increase in ALT levels in patients with OCI versus the negative group. Also, there is a significant increase of history of blood transfusion in patients with occult HCV (p?=?0.03) while the duration of haemodialysis showed no statistical significant difference between both groups. The viral load of the occult hepatitis C virus infection subjects ranged from 581to 74,307 copies/ml.Conclusion
These results highlight the potential risk of hepatitis C virus transmission from patients within haemodialysis units in Egypt. Isolation of patients on dialysis machines depending on the results of hepatitis serological markers is not enough. Testing for hepatitis C virus -RNA in peripheral blood mononuclear cells is more reliable in identifying patients with an OCI when a liver biopsy is not available. 相似文献Background
Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients’ views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adults (AYA). Study objectives were to assess beliefs about hydroxyurea using the Beliefs about Medicines Questionnaire (BMQ), and to examine the relationship of patients’ beliefs to their hydroxyurea adherence and HRQOL.Methods
Thirty-four AYA with SCD participated in a cross-sectional study January–December 2015. Study assessments included BMQ to examine beliefs about hydroxyurea; Visual Analogue Scale (VAS) to assess hydroxyurea adherence; and Patient Reported Outcomes Measurement Information System (PROMIS®) to evaluate HRQOL.Results
Participants (41% female, 91% Black) had median age of 13.5 (IQR 12–18) years. Participants’ concerns about overuse of medications correlated with concerns about hydroxyurea (rs?=?0.36, p?=?0.04) and overall harm of medications (rs?=?0.5, p?=?0.003). Participants’ age positively correlated with the necessity of hydroxyurea (rs?=?0.45, p?=?0.007). Participants’ concerns about hydroxyurea and overuse of medications positively correlated with anxiety (rs?=?0.41, p?=?0.02; rs?=?0.44, p?=?0.01) and depression (rs?=?0.37, p?=?0.04; rs?=?0.54, p?=?0.001), but inversely correlated with peer relationships (rs?=??0.45, p?=?0.03; rs?=??0.44, p?=?0.03), respectively, suggesting better HRQOL with concerns. Fifty percent of participants reported low hydroxyurea adherence (VAS?<?80%), which was more seen in patients with higher concerns about hydroxyurea (p?=?0.02).Conclusions
Beliefs about hydroxyurea correlated with HRQOL scores and adherence levels. Addressing patients’ concern about hydroxyurea and medications overall as well as routine assessment of adherence and beliefs could help to overcome adherence barriers. 相似文献The purpose of the study was to determine if the ≥ 15 mm threshold currently used to define PIRADS 5 lesions is the optimal size threshold for predicting high likelihood of clinically significant (CS) cancers.
MaterialsThree hundred and fifty-eight lesions that may be changed from category 4 to 5 or vice versa on the basis of the size criterion (category 4: n = 288, category 5: n = 70) from 255 patients were evaluated. Kendall’s tau-b statistic accounting for inter-lesion correlation, generalized estimation equation logistic regression, and receiver operating curve analysis evaluated two lesion size-metrics (lesion diameter and relative lesion diameter—defined as lesion diameter/prostate volume) for ability to identify CS (Gleason grade ≥ 3 + 4) cancer at targeted biopsy. Optimal cut-points were identified using the Youden index. Analyses were performed for the whole prostate (WP) and zone-specific sub-cohorts of lesions in the peripheral and transition zones (PZ and TZ).
ResultsLesion diameter showed a modest correlation with Gleason grade (WP: τB = 0.21, p < 0.0001; PZ: τB = 0.13, p = 0.02; TZ: τB = 0.32, p = 0.001), and association with CS cancer detection (WP: AUC = 0.63, PZ: AUC = 0.59, TZ: AUC = 0.74). Empirically derived thresholds (WP: 14 mm, PZ: 13 mm, TZ: 16 mm) performed similarly to the current ≥ 15 mm standard. Lesion relative lesion diameter improved identification of CS cancers compared to lesion diameter alone (WP: τB = 0.30, PZ: τB = 0.24, TZ: τB = 0.42, all p < 0.0001). AUC also improved for WP and PZ lesions (WP: AUC = 0.70, PZ: AUC = 0.68, and TZ: AUC = 0.74).
ConclusionsThe current ≥ 15 mm diameter threshold is a reasonable delineator of PI-RADS category 4 and category 5 lesions in the absence of extraprostatic extension to predict CS cancers. Additionally, relative lesion diameter can improve identification of CS cancers and may serve as another option for distinguishing category 4 and 5 lesions.
相似文献